Phytosterols, Lipid Administration, and Liver Disease during Parenteral Nutrition

Journal of Parenteral and Enteral Nutrition

Volumn 39, Issue , 2015, Pages 39S-60S

  Zaloga, Gary P ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

cholestasis; hepatobiliary function; lipid emulsions; parenteral nutrition; parenteral nutrition associated liver disease; phytosterols

Indexed keywords

BILE ACID; LIPID; LIPID EMULSION; PHYTOSTEROL; FAT INTAKE; VEGETABLE OIL;

BILE ACID BLOOD LEVEL; BILE ACID SYNTHESIS; BILE SECRETION; CHOLESTASIS; CHOLESTEROL METABOLISM; DISEASE ASSOCIATION; DRUG EFFECT; HEPATOBILIARY SYSTEM; HUMAN; LIVER DISEASE; NONHUMAN; PARENTERAL NUTRITION; PARENTERAL NUTRITION ASSOCIATED LIVER DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REHABILITATION; REVIEW; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; ANIMAL; BILE DUCT; CHEMISTRY; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; FAT INTAKE; LIVER; METABOLISM; PATHOLOGY;

ANIMALIA; VERTEBRATA;

ANIMALS; BILE DUCTS; CHOLESTASIS; DIETARY FATS; DRUG-INDUCED LIVER INJURY; FAT EMULSIONS, INTRAVENOUS; HUMANS; LIVER; PARENTERAL NUTRITION; PHYTOSTEROLS; PLANT OILS;

EID: 84939608843     PISSN: 01486071     EISSN: 19412444     Source Type: Journal    
DOI: 10.1177/0148607115595978     Document Type: Review

References (116)

1. Ostlund RE., Phytosterols in human nutrition. Annu Rev Nutr. 2002; 22: 533-549.
2. Trauner M, Meier PJ, Boyer JL,. Molecular pathogenesis of cholestasis. N Engl J Med. 1998; 339: 1217-1227.
3. Ikonen E,. Mechanisms for cellular cholesterol transport: defects and human disease. Physiol Rev. 2006; 86: 1237-1261.
4. Dawson PA, Lan T, Rao A,. Bile acid transporters. J Lip Res. 2009; 50: 2340-2357.
5. Hazard SE, Patel SB,. Sterolins ABCG5 and ABCG8: regulators of whole body dietary sterols. Pflugers Arch. 2007; 435: 745-752.
6. Eloranta JJ, Kullak-Ublick GA,. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch Biochem Biophys. 2005; 433: 397-412.
7. Kurvinen A, Nissinen MJ, Andersson S,. Parenteral plant sterols and intestinal failure-associated liver disease in neonates. J Pediatr Gastroenterol Nutr. 2012; 54: 803-811.
8. Kast HR, Goodwin B, Tarr PT,. Regulation of multidrug resistant associated protein 2 (ABCC2) by the nuclear pregame X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem. 2002; 277: 2908-2915.
9. Wang H, Chen J, Hollister K, Sowers LC, Forman BM,. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell. 1999; 3: 543-553.
10. Carter BA, Taylor OA, Prendergast DR,. Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of bile acid nuclear receptor FXR. Pediatr Res. 2007; 62: 301-306.
11. Zhao A, Yu J, Lew JL, Huang L, Wright SD, Cui J,. Polyunsaturated fatty acids are FXR ligands and differentially regulate expression of FXR targets. DNA Cell Biol. 2004; 23: 519-526.
12. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ,. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000; 102: 731-744.
13. Liu Y, Binz J, Numerick MJ,. Hepatoprotection by farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest. 2002; 112: 1678-1687.
14. Lee JM, Wagner M, Xiao R,. Nutrient sensing nuclear receptors coordinate autophagy. Nature. 2014; 516: 112-115.
15. Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf DJ,. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by liver X receptors α and β. J Biol Chem. 2002; 277: 18793-18800.
16. Schmitz G, Langmann T, Heimesl S,. Role of ABCG1 and other ABCG family members in lipid metabolism. J Lip Res. 2001; 42: 1513-1520.
17. Jia L, Betters JL, Yu L,. Niemann-Pick C1-like1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. Ann Rev Physiol. 2011; 73: 239-259.
18. Kidambi S, Patel SB,. Cholesterol and non-cholesterol sterol transporters: ABCG5, ABCG8, and NPC1L1. A review. Xenobiotica. 2008; 38: 1119-1139.
19. Huff MW, Pollex RL, Hegele RA,. NPC1L1: evolution from pharmacological target to physiological sterol transporter. Arterioscler Thromb Vasc Biol. 2006; 26: 2433-2438.
20. Wittenburg H, Carey MC,. Biliary cholesterol secretion by the twinned sterol half-transporters ABCG5 and ABCG8. J Clin Invest. 2002; 110: 605-609.
21. Sabeva NS, Liu J, Graf GA,. The ABCG5 ABCG8 sterol transporter and phytosterols: implications for cardiometabolic disease. Curr Opin Endocrinol Diabetes Obes. 2009; 16: 172-177.
22. Yu L, Hammer RE, Li-Hawkins J,. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol transport. PNAS. 2002; 99: 16237-16242.
23. El Kasmi KC, Anderson AL, Devereaux MW,. Phytosterols promote liver injury and Kupffer cell activation in parenteral nutrition-associated liver disease. Sci Transl Med. 2013; 5:206ra137.
24. Clayton PT, Whitfield P, Iyer K,. The role of phytosterols in the pathogenesis of liver complications of pediatric parenteral nutrition. Nutrition. 1998; 14: 158-164.
25. Tazuke Y, Kiristioglu I, Heidelberger KP, Eisenbraun MD, Teitelbaum DH,. Hepatic P-glycoprotein changes with total parenteral nutrition administration. JPEN J Parenter Enteral Nutr. 2004; 28: 1-6.
26. Tazuke Y, Teitelbaum DH,. Alteration of canalicular transporters in a mouse model of total parenteral nutrition. J Pediatr Gastroenterol Nutr. 2009; 48: 193-202.
27. Whitfield PD, Clayton PT, Muller DPR,. Effect of intravenous lipid emulsions on hepatic cholesterol metabolism. J Pediatr Gastroenterol Nutr. 2000; 30: 538-546.
28. Boberg KM, Akerlund JE, Bjorkhem I,. Effect of Sitosterol on the rate-limiting enzymes in cholesterol synthesis and degradation. Lipids. 1989; 24: 9-12.
29. Vlaardingerbroek H, Ng K, Stoll B,. New generation lipid emulsions prevent PNALD in chronic parenterally-fed preterm pigs. J Lip Res. 2014; 55: 466-477.
30. Shefer S, Salen G, Nguyen L,. Competitive inhibition of bile acid synthesis by endogenous cholestanol and sitosterol in sitosterolemia with xanthomatosis. J Clin Invest. 1988; 82: 1833-1839.
31. Nguyen LB, Shefer S, Salen G, Tint SG, Batta AK,. Competitive inhibition of hepatic sterol 27-hydroxylase by sitosterol: decreased activity in sitosterolemia. Proc Assoc Am Physicians. 1998; 110: 32-39.
32. Peden VH, Witzleben CL, Skelton MA,. Total parenteral nutrition. J Pediatr. 1971; 78: 180.
33. Farrell MK, Balistreri WF,. Parenteral nutrition and hepatobiliary dysfunction. Clin Perinatol. 1986; 13: 197-212.
34. Touloukian RJ, Seashore JH,. Hepatic secretory obstruction with total parenteral nutrition in the infant. J Pediatr Surg. 1975; 10: 353-360.
35. Beale EF, Nelson RM, Bucciarelli RL, Donnelly WH, Eitzman DV,. Intahepatic cholestasis associated with parenteral nutrition in premature infants. Pediatrics. 1979; 64: 342-347.
36. Nehra D, Fallon EM, Carlson SJ,. The prevention and treatment of intestinal failure-associated liver disease in neonates and children. Surg Clin N Am. 2011; 91: 543-563.
37. Kelly DA,. Preventing parenteral nutrition liver disease. Early Human Dev. 2010; 86: 683-687.
38. Cavicchi M, Beau P, Crenn P, Degott C, Messing B,. Prevelance of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med. 2000; 132: 525-532.
39. Diamond IR, de Silva NT, Tomlinson GE,. The role of parenteral lipids in the development of advanced intestinal failure-associated liver disease in infants: a multiple-variable analysis. JPEN J Parenter Enteral Nutr. 2011; 35: 596-602.
40. Duro D, Mitchell PD, Kalish LA,. Risk factors for parenteral nutrition-associated liver disease following surgical therapy for necrotizing enterocolitis. J Pediatr Gastroenterol Nutr. 2011; 52: 595-600.
41. Lloyd DAJ, Gabe SM,. Managing liver dysfunction in parenteral nutrition. Proc Nutr Soc. 2007; 66: 530-538.
42. Luman W, Shaffer JL,. Prevalence, outcome and associated factors of deranged liver function tests in patients on home parenteral nutrition. Clin Nutr. 2002; 21: 337-343.
43. Tomer G, Ananthanarayanan M, Weymann A, Balasubramanian N, Suchy FJ,. Differential developmental regulation of rat liver canalicular membrane transporters BSEP and MRP2. Pediatr Res. 2003; 53: 288-294.
44. Chen HL, Chen HL, Liu YJ,. Developmental expression of canalicular transporter genes in human liver. J Hepatol. 2005; 43: 472-477.
45. Beath SV, Davies P, Papadopoulou A,. Parenteral nutrition-related cholestasis in postsurgical neonates: multivariate analysis of risk factors. J Pediatr Surg. 1996; 31: 604-606.
46. Christensen RD, Henry E, Wiedmeier SE, Burnett J, Lambert DK,. Identifying patients, on the first day of life, at high-risk of developing parenteral nutrition-associated liver disease. J Perinatol. 2007; 27: 284-290.
47. Zimmerman TL, Thevananther S, Ghose R, Burns AR, Karpen SJ,. Nuclear export of retinoid X receptor (alpha) in response to interleukin-1beta-mediated cell signaling: roles of JNK and SER260. J Biol Chem. 2006; 281: 15434-15440.
48. Moseley RH, Wang W, Takeda H,. Effect of endotoxin on bile acid transport in rat liver: a potential model for sepsis-associated cholestasis. Am J Physiol. 1996; 271: G137-G146.
49. Allardyce DB., Cholestasis caused by lipid emulsions. Surg Gynecol Obstet. 1982; 154: 641-647.
50. Nehra D, Fallon EM, Carlson SJ,. Provision of a soy-based intravenous lipid emulsion at 1 g/kg/d does not prevent cholestasis in neonates. JPEN J Parenter Enteral Nutr. 2013; 37: 498-505.
51. Puder M, Valim C, Meisel JA,. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg. 2009; 250: 395-402.
52. Nayrouz MM, Amin SB,. Cumulative amount of intravenous lipid intake and parenteral nutrition-associated cholestasis in neonates with gastrointestinal surgical disorders. Am J Perinatol. 2014; 31: 419-424.
53. Xu Z, Harvey KA, Pavlina T,. Steroidal compounds in commercial parenteral lipid emulsions. Nutrients. 2012; 4: 904-921.
54. Forchielli ML, Bersani G, Tala S, Grossi G, Puggioli C, Masi M,. The spectrum of plant and animal sterols in different oil-derived intravenous emulsions. Lipids. 2010; 45: 63-71.
55. Ellegard L, Sunesson A, Bosaeus I,. High serum phytosterol levels in short bowel patients on parenteral nutrition support. Clin Nutr. 2005; 24: 415-420.
56. La Scala GC, Le Coultre C, Roche BG, Bugmann P, Belli DC,. The addition of lipids increases the total parenteral nutrition-associated cholestasis in the rat. Eur J Pediatr Surg. 1993; 3: 224-227.
57. Penco JMM, Botejara EM, Martinez JS,. Liver lipid composition and intravenous, intraperitoneal, and enteral administration of Intralipid. Nutrition. 1994; 10: 26-31.
58. Chen WJ, Yeh SL, Huang PC,. Effects of fat emulsions with different fatty acid composition on plasma and hepatic lipids in rats receiving total parenteral nutrition. Clin Nutr. 1996; 15: 24-28.
59. Yeh SL, Chen WJ, Huang PC,. Effects of fish oil and safflower oil emulsions on diet-induced hepatic steatosis in rats receiving total parenteral nutrition. Clin Nutr. 1996; 15: 80-83.
60. Hyde MJ, Amusquivar E, Laws J,. Effects of lipid-supplemented total parenteral nutrition on fatty liver disease in a premature neonatal piglet model. Neonatology. 2008; 93: 77-86.
61. Kohl M, Wedel T, Entenmann A,. Influence of different intravenous lipid emulsions on hepatobiliary dysfunction in a rabbit model. J Pediatr Gastroenterol Nutr. 2007; 44: 237-244.
62. Tazuke Y, Teitelbaum D, Wasa M, Fukuzawa M, Liboshi Y, Fujimoto J,. Parenteral nutrition administration leads to specific alterations in the expression of adipocytokines and peroxisome proliferator-activated receptors in a rat model. JPEN J Parenter Enteral Nutr. 2011; 35: 329-336.
63. Javid PJ, Greene AK, Garza J,. The route of lipid administration affects parenteral nutrition-induced hepatic steatosis in a mouse model. J Pediatr Surg. 2005; 40: 1446-1453.
64. Alwayn IPJ, Gura K, Nose V,. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res. 2005; 57: 445-452.
65. Prince E, Lazare FB, Treem WR,. ‰-3 fatty acids prevent hepatic steatosis, independent of PPAR-α activity, in a murine model of parenteral nutrition associated liver disease. JPEN J Parenter Enteral Nutr. 2013; 38: 608-616.
66. Iyer KR, Spitz L, Clayton P,. New insight into mechanisms of parenteral nutrition-associated cholestasis: Role of plant sterols. J Pediatr Surg. 1998; 33: 1-6.
67. Van Aerde JE, Duerksen DR, Gramlich L,. Intravenous fish oil emulsion attenuates total parenteral nutrition-induced cholestasis in newborn piglets. Pediatr Res. 1999; 45: 202-208.
68. Meisel JA, Le HD, De Meijer VE,. Comparison of 5 intravenous lipid emulsions and their effects on hepatic steatosis in a murine model. J Pediatr Surg. 2011; 46: 666-673.
69. Zhu X, Xiao Z, Chen X,. Parenteral nutrition-associated liver injury and increased GRP94 expression prevented by ‰-3 fish oil-based lipid emulsion supplementation. J Pediatr Gastroenterol Nutr. 2014; 59: 708-713.
70. Harvey K, Xu Z, Walker C,. Parenteral lipid emulsions in guinea pigs differentially influence plasma and tissue levels of fatty acids, squalene, cholesterol, and phytosterols. Lipids. 2014; 49: 777-793.
71. Clayton PT, Bowron A, Mills KA, Massoud A, Casteels M, Milla PJ,. Phytosterolemia in children with parenteral nutrition-associated cholestatic liver disease. Gastroenterology. 1993; 105: 1806-1813.
72. Bindl L, Lutjohann D, Buderus S, Lentze MJ, Bergmann KV,. High plasma levels of phytosterols in patients on parenteral nutrition: a marker of liver dysfunction. J Pediatr Gastroenterol Nutr. 2000; 31: 313-316.
73. Llop JM, Virgili N, Moreno-Villares JM,. Phytosterolemia in parenteral nutrition patients: implications for liver disease development. Nutrition. 2008; 24: 1145-1152.
74. Pianese P, Salvia G, Campanozzi A,. Sterol profiling in red blood cell membranes and plasma of newborns receiving total parenteral nutrition. J Pediatr Gastroenterol Nutr. 2008; 47: 645-651.
75. Kurvinen A, Nissinen MJ, Gylling H,. Effects of long-term parenteral nutrition on serum lipids, plant sterols, cholesterol metabolism, and liver histology in pediatric intestinal failure. J Pediatr Gastroenterol Nutr. 2011; 53: 440-446.
76. Dimakou K, Guillotte C, Hill S,. Phytosterols of HPN patients [abstract]. Clin Nutr. 2012; 7 (1): 135.
77. Allardyce DB, Salvian AJ, Quenville NF,. Cholestatic jaundice during total parenteral nutrition. Can J Surg. 1978; 21: 332-339.
78. Salvian AJ, Allardyce DB,. Impaired bilirubin secretion during total parenteral nutrition. J Surg Res. 1980; 28: 547-555.
79. Colomb V, Jobert-Giraud A, Lacaille F, Goulet O, Fournet JC, Ricour C,. Role of lipid emulsions in cholestasis associated with long term parenteral nutrition in children. JPEN J Parenter Enteral Nutr. 2000; 24: 345-350.
80. Shin JI, Namgung R, Park MS, Lee C,. Could lipid infusion be a risk for parenteral nutrition-associated cholestasis in low birth weight neonates? Eur J Pediatr. 2008; 167: 197-202.
81. Cober MP, Killu G, Brattain A, Welch KB, Kunisake SM, Teitelbaum DH,. Intravenous fat emulsions reduction for patients with parenteral nutrition-associated liver disease. J Pediatr. 2012; 160: 421-427.
82. Cober MP, Teitelbaum DH,. Prevention of parenteral nutrition-associated liver disease: lipid minimization. Curr Opin Organ Transplant. 2010; 15: 330-333.
83. Sanchez SE, Braun LP, Mercer LD, Sherrill M, Stevens J, Javid PJ,. The effect of lipid restriction on the prevention of parenteral nutrition-associated cholestasis in surgical patients. J Pediatr Surg. 2013; 48: 573-578.
84. Reimund JM, Arondel Y, Joly F, Messing B, Duclos B, Baumann R,. Potential usefulness of olive-oil based lipid emulsions in selected situations of home parenteral nutrition-associated liver disease. Clin Nutr. 2004; 23: 1418-1425.
85. Hallikainen M, Huikko L, Kontra K,. Effect of parenteral serum plant sterols on liver enzymes and cholesterol metabolism in a patient with short bowel syndrome. Nutr Clin Pract. 2008; 23: 429-435.
86. Palova S, Charvat J, Kvapil M,. Comparison of soybean oil and olive oil-based lipid emulsions on hepatobiliary function and serum triacylglycerols level during realimentation. J Intern Med Res. 2008; 36: 587-593.
87. Pawlik D, Lauterbach R, Turyk E,. Fish oil fat emulsion supplementation may reduce the risk of severe retinopathy in VLBW infants. Pediatrics. 2011; 127: 223-228.
88. Angsten G, Finkel Y, Lucas S, Kassa AM, Paulsson M, Lilja HE,. Improved outcome in neonatal short bowel syndrome using parenteral fish oil in combination with ‰-6/9 lipid emusions. JPEN J Parenter Enteral Nutr. 2012; 36: 587-595.
89. Lilja HE, Finkel Y, Paulsson M, Lucas S,. Prevention and reversal of intestinal failure-associated liver disease in premature infants with short bowel syndrome using intravenous fish oil in combination with omega-6/9 lipid emulsions. J Pediatr Surg. 2011; 46: 1361-1367.
90. Xu Z, Li Y, Wang J, Wu B, Li J,. Effect of omega-3 polyunsaturated fatty acids to reverse biopsy-proven parenteral nutrition-associated liver disease in adults. Clin Nutr. 2012; 31: 217-223.
91. Diamond IR, Sterescu A, Pencharz PB, Kim JH, Wales PW,. Changing the paradigm: Omegaven for the treatment of liver failure in pediatric short bowel syndrome. J Pediatr Gastroenterol Nutr. 2009; 48: 209-215.
92. Diamond IR, Sterescu A, Pencharz PB, Wales PW,. The rationale for the use of parenteral omega-3 lipids in children with short bowel syndrome and liver disease. Pediatr Surg Int. 2008; 24: 773-778.
93. Klek S, Chambrier C, Singer P,. Four-week parenteral nutrition using a third generation lipid emulsion (SMOFlipid): a double-blind, randomized, multicenter study in adults. Clin Nutr. 2013; 32: 224-231.
94. Goulet O, Antebi H, Wolf C,. A new intravenous fat emulsion containing soybean oil, medium-chain triglycerides, olive oil, and fish oil: A single-center, double-blind randomized study on efficacy and safety in pediatric patients receiving home parenteral nutrition. JPEN J Parenter Enteral Nutr. 2010; 34: 485-495.
95. Muhammed R, Bremner R, Protheroe S, Johnson T, Holden C, Murphy MS,. Resolution of parenteral nutrition-associated jaundice on changing from a soybean oil emulsion to a complex mixed-lipid emulsion. J Pediatr Gastroenterol Nutr. 2012; 54: 797-802.
96. Rayyan M, Devlieger H, Jochum F, Allegaert K,. Short-term use of parenteral nutrition with a lipid emulsion containing a mixture of soybean oil, olive oil, medium-chain triglycerides, and fish oil: a randomized double-blind study in preterm infants. JPEN J Parenter Enteral Nutr. 2012; 36: 81S-94S.
97. Skouroliakou M, Konstantinou D, Agakidis C,. Cholestasis, bronchopulmonary dysplasia, and lipid profile in preterm infants receiving MCT/‰-3-PUFA-containing or soybean-based lipid emulsions. Nutr Clin Pract. 2012; 27: 817-824.
98. Pichler J, Simchowitz V, Macdonald S, Hill S,. Comparison of liver function with two new/mixed intravenous lipid emulsions in children with intestinal failure [published online June 25, 2014]. Eur J Clin Nutr.
99. Tomsits E, Pataki M, Tolgyesi A, Fekete G, Rischak K, Szollar L,. Safety and efficacy of a lipid emulsion containing a mixture of soybean oil, medium-chain triglycerides, olive oil, and fish oil: a randomized, double-blind clinical trial in premature infants requiring parenteral nutrition. J Pediatr Gastroenterol Nutr. 2010; 51: 514-521.
100. Skouroliakou M, Konstantinou D, Koutri K,. A double-blind, randomized clinical trial of the effect of ‰-3 fatty acids on the oxidative stress of preterm neonates fed through parenteral nutrition. Eur J Clin Nutr. 2010; 64: 940-947.
101. Savini S, DAscenzo R, Biagetti C,. The effect of 5 intravenous lipid emulsions on plasma phytosterols in preterm infants receiving parenteral nutrition: a randomized clinical trial. Am J Clin Nutr. 2013; 98: 312-318.
102. DAscenzo R, Savini S, Biagetti C,. Higher docosahexaenoic acid, lower arachidonic acid and reduced lipid tolerance with high doses of a lipid emulsion containing 15% fish oil: a randomized clinical trial. Clin Nutr. 2014; 33: 1002-1009.
103. Deshpande G, Simmer K, Deshmukh M, Mori TA, Croft KD, Kristensen J,. Fish oil (SMOFlipid) and olive oil lipid (Clinoleic) in very premature neonates. J Pediatr Gastroenterol Nutr. 2014; 58: 177-182.
104. Vlaardingerbroek H, Vermeulen MJ, Carnielli VP, Vaz FM, van den Akker CHP, van Goudoever JB,. Growth and fatty acid profiles of VLBW infants receiving a multicomponent lipid emulsion from birth. J Pediatr Gastroenterol Nutr. 2014; 58: 417-427.
105. Beken S, Dilli D, Fettah ND, Kabatas EU, Zenciroglu A, Okumus N,. The influence of fish-oil emulsions on retinopathy of prematurity in very low birth weight infants: a randomized controlled trial. Early Hum Dev. 2014; 90: 27-31.
106. Gura KM, Duggan CP, Collier SB,. Reversal of parenteral nutrition-associated liver disease in 2 infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics. 2006; 118: e197-e201.
107. Ekema G, Falchetti D, Boroni G,. Reversal of severe parenteral nutrition-associated liver disease in an infant with short bowel syndrome using parenteral fish oil (omega-3 fatty acids). J Pediatr Surg. 2008; 43: 1191-1195.
108. Gura KM, Lee S, Valim C,. Safety and efficacy of fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics. 2008; 121: e678-e686.
109. Premkumar MH, Carter BA, Hawthorne KM, King K, Abrams SA,. Fish oil-based lipid emulsions in the treatment of parenteral nutrition-associated liver disease: an ongoing positive experience. Adv Nutr. 2014; 5: 65-70.
110. Premkumar MH, Carter BA, Hawthorne KM, King K, Abrams SA,. High rates of resolution of cholestasis in parenteral nutrition-associated liver disease with fish oil-based lipid emulsion monotherapy. J Pediatr. 2013; 162: 793-798.
111. Khan FA, Fisher JG, Sparks EA,. Preservation of biochemical liver function with low-dose soy-based lipids in children with intestinal failure-associated liver disease. J Pediatr Gastroenterol Nutr. 2015; 60: 375-377.
112. Lam HS, Tam YH, Poon TCW,. A double-blind randomized controlled trial of fish oil-based versus soybean oil-based lipid preparations in the treatment of infants with parenteral nutrition-associated cholestasis. Neonatology. 2014; 105: 290-296.
113. Venecourt-Jackson E, Hill SJ, Walmsley RS,. Successful treatment of parenteral nutrition-associated liver disease in an adult by use of a fish oil-based lipid source. Nutrition. 2013; 29: 356-358.
114. Burns DL, Gill BM,. Reversal of parenteral nutrition-associated liver disease with a fish oil-based lipid emulsion (Omegaven) in an adult dependent on home parenteral nutrition. JPEN J Parenter Enteral Nutr. 2013; 37: 274-280.
115. Torres C, Sudan D, Vanderhoof J,. Role of an intestinal rehabilitation program in the treatment of advanced intestinal failure. J Pediatr Gastroenterol Nutr. 2007; 45: 204-212.
116. Cowles RA, Ventura KA, Martinez M,. Reversal of intestinal failure-associated liver disease in infants and children on parenteral nutrition: experience with 93 patients at a referral center for intestinal rehabilitation. J Pediatr Surg. 2010; 45: 84-88.